Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation

Radiotherapy and Oncology

Volumn 70, Issue 3, 2004, Pages 311-317

  Kim, Joo Young ^a,c   West, C M L ^a   Valentine, H ^a   Ward, T H ^a   Patterson, A V ^b   Stratford, I J ^b   Roberts, S A ^b   Hendry, J H ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c National Cancer Center   (South Korea)

Author keywords

Bioreductive agent; DT diaphorase; Hypoxia; Radiosensitizers; RH1

Indexed keywords

2,5 DIAZIRIDINYL 3 (HYDROXYMETHYL) 6 METHYL 1,4 BENZOQUINONE; CYTOCHROME P450 REDUCTASE; CYTOTOXIC AGENT; ENZYME; NITROGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCING AGENT; RH 1; UNCLASSIFIED DRUG;

AIR; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL LEVEL; CELL LINE; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ANALYSIS; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IONIZING RADIATION; IRRADIATION; PRIORITY JOURNAL; RADIATION; RADIOSENSITIZATION; TIME;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOQUINONES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; RADIATION-SENSITIZING AGENTS; TRANSFECTION; TUMOR STEM CELL ASSAY;

EID: 1942503333     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2003.12.008     Document Type: Article

References (23)

1. Adams G.E., Breccia A., Fielden E.M., Wardman P. Selective activation of drugs by redox processes. Proceedings of a NATO Advanced Research Workshop on Selective Activation of Drugs by Redox Processes, held August 28-September 1. 1989;Plenum Press, New York.
2. Adams G.E., Stratford I.J. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys. 29:(2):1994;231-238.
3. Alexander P., Gielen J., Sartorelli A.C. Bioreduction in the activation of drugs. Proceedings of the Second Biochemical Pharmacology Symposium, Oxford, UK, July. 1985;Pergamon Press, Oxford.
4. 1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol. 42:(5):1991;1021-1027.
5. De Cerain A.L., Marín A., Idoate M.A., Tuñón M.T., Bello J. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer. 35:(2):1999;320-324.
6. Elliott M.A., Ford S.J., Walker A.A., Hargreaves R.H., Halbert G.W. Development of a lyophilised RH1 formulation: a novel DT diaphorase activated alkylating agent. J Pharm Pharmacol. 54:(4):2002;487-492.
7. Houlbrook S., Kirk J., Stuart N.S.A., Stradtford I.J., Harris A.L., Pettit G.R., Carmichael J. Human tumour cell lines: a valuable model for the evaluation of new drugs and for the evaluation of mechanisms underlying cytotoxic drug resistance. Oncol (Life Sci Adv). 13:1994;69-76.
8. Miyamoto S., Huang T.T., Wuerzberger-Davis S., et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann N Y Acad Sci. 922:2000;274-292.
9. Patterson A.V., Robertson N., Houlbrook S., et al. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int J Radiat Oncol Biol Phys. 29:1994;369-372.
10. Patterson A.V., Barham H.M., Chinje E.C., Adams G.E., Harris A.L., Stratford I.J. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer. 72:1995;1144-1150.
11. Patterson A.V., Saunders M.P., Chinje E.C., Talbot D.C., Harris A.L., Stratford I.J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer. 76:1997;1338-1347.
12. Planchon S.M., Pink J.J., Tagliarino C., Bormann W.G., Varnes M.E., Boothman D.A. beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp Cell Res. 267:(1):2001;95-106.
13. Plumb J.A., Gerristsen M., Milroy R., Thomson P., Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys. 29:(2):1994;295-299.
14. Robertson N., Haigh A., Adams G.E., Stratford I.J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer. 30A:(7):1994;1013-1019.
15. Rockwell S., Keyes S.R., Sartoreli A.C. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res. 116:1988;100-113.
16. Rockwell S., Hughes C.S. Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures. Cell Prolif. 27:1994;153-163.
17. S-Plus. Insightful Corp., Seattle, WA, USA.
18. Saunders M.P., Patterson A.V., Chinje E.C., Harris A.L., Stratford I.J. NADPH: cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer. 82:(3):2000;561-566.
19. Smitskamp-Wilms E., Giaccone G., Pinedo H.M., van der Laan B.F.A.M., Peters G.J. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer. 72:1995;917-921.
20. Ward T.H., Coe N., Hargreaves R., Butler J., McGown A.T. Toxicity, cellular uptake and DNA crosslinking studies on the novel bioreductive anticancer drug RH1. Br J Cancer. 83:(Suppl 1):2000;66.
21. Winski S.L., Hargreaves R.H.J., Butler J., Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res. 4:1998;3083-3088.
22. Winski S.L., Swann E., Hargreaves R.H.L., Dehn D.L., Butler J., Moody C.J., Ross D. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol. 61:2001;1509-1516.
23. Wu K., Eng E., Knox R., Chen S. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and a mouse xenograft model. Arch Biochem Biophys. 385:2001;203-208.